{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:03:39Z","timestamp":1779858219806,"version":"3.53.1"},"reference-count":20,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States. Prevention strategies are recommended to mitigate severe RSV outcomes. In addition to identifying potential coverage gaps, preventative administration timing is important for estimating product effectiveness. This study characterized administration timing of maternal and infant immunization against RSV across the United States during the 2024\u20132025 RSV season. Methods: A retrospective cross-sectional study was conducted using administrative claims of a commercially insured population from Kythera Labs. Pregnant individuals who received RSVpreF vaccine and infants who received nirsevimab were included. The seasonal cohort included infants born during the RSV season, while infants born from April to September were considered as the catch-up cohort. Baseline characteristics and calendar month and age at immunization (gestational age for RSVpreF) were evaluated. Results: Overall, 37,686 (71.9%) of maternal vaccinations were administered at 32\u201334 gestational weeks and 92.7% of all vaccinations occurred \u226514 days before delivery. Among infants who received nirsevimab, 34.8% of the seasonal cohort were immunized within 1 week of birth and 33.4% of the catch-up cohort were immunized in October 2024. Conclusions: Most maternal RSVpreF vaccinations occurred early in the recommended eligible gestational age window, while only approximately one-third of infants received nirsevimab during the first week of life or at the beginning of the RSV season. These findings highlight the importance of timely administration of RSV preventives. They further demonstrate that immunization timing should be incorporated into evaluation of the effectiveness and population level impact of RSV prevention programs.<\/jats:p>","DOI":"10.3390\/vaccines14060471","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:57:44Z","timestamp":1779710264000},"page":"471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Administration Timing of Respiratory Syncytial Virus Preventatives Among Commercially Insured Populations in the United States: 2024\u20132025 RSV Season"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8030-3733","authenticated-orcid":false,"given":"Amy W.","family":"Law","sequence":"first","affiliation":[{"name":"Pfizer, Inc., New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2107-7296","authenticated-orcid":false,"given":"Danielle C.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-3767","authenticated-orcid":false,"given":"Marjan","family":"Zakeri","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics, New York, NY 10013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehir","family":"Yapar","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics, New York, NY 10013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4310-0032","authenticated-orcid":false,"given":"Alexandra","family":"Passarelli","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics, New York, NY 10013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-5672","authenticated-orcid":false,"given":"Onur","family":"Baser","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics, New York, NY 10013, USA"},{"name":"Graduate School of Public Health, City University of New York (CUNY), New York, NY 10027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1340-8905","authenticated-orcid":false,"given":"Pia D. M.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref_1","unstructured":"(2026, February 28). RSV in Infants and Young Children. Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/rsv\/infants-young-children\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/rsv\/high-risk\/infants-young-children.html."},{"key":"ref_2","unstructured":"(2026, February 06). Effectiveness and Impact of RSV Prevention Products in Infants During the 2024\u20132025 RSV Season, Available online: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-06-25-26\/03-MacNeil-Mat-Peds-RSV-508.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1093\/infdis\/jiac155","article-title":"Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011\u20132019","volume":"226","author":"Suh","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2023062574","DOI":"10.1542\/peds.2023-062574","article-title":"Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020","volume":"153","author":"Curns","year":"2024","journal-title":"Pediatrics"},{"key":"ref_5","unstructured":"(2026, January 29). RSV Vaccine Guidance for Pregnant Women. US Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/pregnant-people.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2025073923","DOI":"10.1542\/peds.2025-073923","article-title":"Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement","volume":"156","author":"Campbell","year":"2025","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2023065623","DOI":"10.1542\/peds.2023-065623","article-title":"Respiratory Syncytial Virus-Associated Hospitalizations in Children <5 Years: 2016\u20132022","volume":"154","author":"McMorrow","year":"2024","journal-title":"Pediatrics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.15585\/mmwr.mm7411a1","article-title":"Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus\u2014United States, 2014\u20132024","volume":"74","author":"Jobe","year":"2025","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e250380","DOI":"10.1001\/jamanetworkopen.2025.0380","article-title":"Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus","volume":"8","author":"Xu","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"554.e1","DOI":"10.1016\/j.ajog.2024.10.053","article-title":"Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth","volume":"232","author":"Jasset","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial","volume":"145","author":"Pahud","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.15585\/mmwr.mm7431a3","article-title":"Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination\u2014United States, October 2023\u2013March 2024; US Centers for Disease Control and Prevention","volume":"74","author":"Boundy","year":"2025","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_14","unstructured":"(2025, July 20). Implementation and Uptake of Nirsevimab and Maternal Vaccine for Infant Protection from RSV. National Center for Immunization and Respiratory Diseases, Available online: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-06-25-26\/02-Peacock-Mat-Peds-RSV-508.pdf."},{"key":"ref_15","unstructured":"Kythera Labs (2025, December 15). Kythera Labs, 2024. Available online: https:\/\/www.kytheralabs.com."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200107123450205","article-title":"Neighborhood of residence and incidence of coronary heart disease","volume":"345","author":"Merkin","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s40264-021-01113-8","article-title":"Validating Claims-Based Algorithms Determining Pregnancy Outcomes and Gestational Age Using a Linked Claims-Electronic Medical Record Database","volume":"44","author":"Moll","year":"2021","journal-title":"Drug Saf."},{"key":"ref_18","unstructured":"(2026, March 10). RSV Immunization Administration Frequently Asked Questions. American Academy of Pediatrics. Available online: https:\/\/www.aap.org\/en\/patient-care\/respiratory-syncytial-virus-rsv-prevention\/rsv-frequently-asked-questions\/?srsltid=AfmBOopZ_l5L-xvhdruRLuU3gAWQwAHVQ66-jbqgnK9jNyQF93Q5ewfq."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.15585\/mmwr.mm7437a2","article-title":"Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus\u2014United States, October 2023-March 2025","volume":"74","author":"Olmsted","year":"2025","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:22:12Z","timestamp":1779855732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vaccines14060471"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14060471","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}